Cipla Q1: consolidated PAT down 39% YoY to ₹786 Cr on US Revlimid/Lanreotide loss
PAT -39.2% YoY · revenue +2.3% · margins compressing · miss vs street
₹7,119.28 Cr
+2.3% YoY
₹785.55 Cr
-39.2% YoY
10.72%
-7.2pp YoY
₹9.77
Cipla opened FY27 with a soft print as consolidated net profit fell 39.2% year-on-year to ₹785.55 Cr (from ₹1,291.61 Cr in Q1 FY26) on near-flat revenue of ₹7,119.28 Cr (+2.3% YoY). The headline QoQ optics look strong — PAT up 44.8% and revenue up 8.8% — but that is off a weak Q4 FY26 base (₹542.51 Cr PAT, dented by an impairment) and is not the story; the year-on-year comparison is, and it is a clear step down against a very strong year-ago quarter.
Q1 FY-2027 vs prior quarters
The damage is entirely at the margin line. EBITDA margin compressed to ~16.8% from 25.6% a year ago, and net margin fell to 11.0% from 17.9%, as the high-margin US portfolio rolled off — the loss of generic Revlimid revenue and the absence of Lanreotide supplies, exactly the headwinds brokerages had flagged. Cost of materials and purchases held broadly flat but employee cost (₹1,497 Cr, +14% YoY) and depreciation (₹304 Cr, +20% YoY) rose, so the operating deleverage on a flat topline drove the profit fall. There was no exceptional item this quarter, so the drop is clean and operational rather than accounting-driven — unlike FY26, which carried a ₹275.91 Cr labour-code charge.
The stock went into the print at ₹1,424.1, down 0.6% over the past month of trading.
What the summary numbers don't show
Standalone PAT ₹862.16 Cr on revenue ₹5,077.68 Cr — EPS (basic, not annualised) ₹9.77 consolidated / ₹10.67 standalone
Management guides for FY27 EBITDA margins of 18.5% to 20%, anticipating sequential improvement with a stronger second half driven by new product launches. The company aims for its North America business to reach a $1 billion revenue run rate by the end of FY27, fueled by its respiratory and complex generics pipeline, w
— This quarter: met
The result missed the street: Nuvama had modelled revenue +5.9% and PAT −30.7% YoY, and Motilal Oswal expected US sales down ~28%; Cipla came in weaker on both topline (+2.3%) and bottom line (−39%). Against management's own FY27 guidance — EBITDA margin of 18.5–20% with an explicitly H2-weighted, new-launch-driven ramp, a $1bn US run-rate by FY27-end (excluding Lanreotide), and market-beating double-digit India growth — Q1's ~16.8% margin runs below the band but is consistent with the guided back-ended shape; the guidance is intact but now visibly H2-dependent. Concurrent corporate developments this quarter were largely governance/housekeeping (90th AGM, appointment of B S R & Co. as statutory auditor, one USFDA observation at a subsidiary, an ESG rating revised down to 64) and did not move the numbers. Standalone PAT of ₹862.16 Cr exceeded consolidated, reflecting a ₹34.33 Cr aggregate net loss across the overseas/subsidiary base.
W1
Margin recovery toward the guided FY27 EBITDA band of 18.5–20% (Q1 ~16.8%) — needs H2 acceleration from new launches
W2
US business trajectory toward the $1bn run-rate by FY27-end (excl Lanreotide) after the Revlimid/Lanreotide roll-off
W3
India 'market-beating double-digit' growth claim — verify against Q2 domestic revenue
Clean digital PDF, unambiguous headers; current column = 30-06-2026 (unaudited, limited review, unmodified). No exceptional item this quarter (prior-year FY26 ₹275.91 Cr labour-code charge sits in the full-year column, not in Q1 FY26). Consolidated 'net profit for the period' ₹785.55 Cr (owners of parent ₹789.05 Cr; NCI −₹3.50 Cr; share of associate loss −₹1.55 Cr). 14 unreviewed subsidiaries posted net loss ₹34.33 Cr, so standalone PAT (₹862.16 Cr) > consolidated. Effective Q1 FY27 certain marketing/promo spend is netted against revenue (₹115.24 Cr in the Q1 FY26 comparative) — presentation-only, no P&L impact.
Record revenue masks earnings collapse and margin shortfall
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Q1 EBITDA margin (16.7%) below guided floor (18.5%). Management cites "transit phase" but no quarters-to-recovery specified. Prior $1B guidance still pending.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Record Q1 revenue masks sharp 39% PAT decline and 180 bps EBITDA shortfall vs guidance. Management attributes weakness to temporary launch capex and war costs (1-2% of revenue), but provides no recovery timeline. North America growth dependent on 4 binary FDA approvals; South Africa tender decline ongoing. Reaffirmed $1B and 18.5-20% guidance but execution risk high.
₹7119.3 Cr
Revenue · +2.3% YoY₹785.5 Cr
Reported PAT · −39.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Highest ever Q1 revenue at ₹7,100 Cr
METDelivered ₹7,119.3 Cr; claim verified
One India 12% YoY growth reflects strong base business momentum
OVERSTATEDYurpeak ₹80 Cr = ~1.5% of growth; organic ex-new products ~7-8% per analyst calc
EBITDA margin broadly unchanged vs 18.5-20% FY27 guidance
MISSQ1 delivered 16.7% EBITDA (call disclosure), 180 bps below guidance floor
PAT ₹789 Cr this quarter
METDelivered ₹785.5 Cr; negligible variance
$1B North America exit run rate achievable with 4 launches
MixedQ1 $162M; needs $938M more in 9 months from binary approvals; Advair now $50-100M peak (not $100M+)
South Africa private market growing 6.5% faster than market 5.7%
METVerified per management; reported headline -5% due to tender decline + currency headwind
Earnings quality
What changed since the last call
EBITDA margin guidance reaffirmed but Q1 misses
NeutralPrior: 18.5-20% for FY27. Q1 delivered 16.7%. Management maintains 18.5-20% is "broadly unchanged" but now contingent on new launches. Adds execution risk to guidance.
North America exit rate ($1B) maintained despite slower Q1 $162M
NeutralPrior: $1B by end FY27. Q1: $162M (2.3% of annual target with 75% of year remaining). Requires 6.2x growth via new approvals—binary and timing dependent.
Lanreotide pushed out; not in FY27 revenue
WithdrawnPrior Q4 call: Potential FY27 revenue. Now: Two-pronged approach (FDA remediation + site transfer) with "timing fluid." Explicitly excluded from projections.
India organic growth slowing; Yurpeak contribution isolated
DowngradeReported 12% Q1 YoY. Analysts calculated ~7-8% ex-Yurpeak (₹80 Cr = 1.5% of total growth). Management didn't rebut; implies base organic momentum weaker than headline.
South Africa tender decline ongoing; private market bright but masked
DowngradePrior: Private market outperformance. Q1: -5% reported, but 6.5% private market growth overshadowed by 23% currency tailwind loss + tender decline (expected to continue).
The Q&A
Strong analyst skepticism in Q&A. Saion Mukharji pushed on real India growth (questioned 12% after adjustments, landed on 7-8%), South Africa tender dynamics (currency-adjusted numbers show weakness). Vivek Agrawal challenged margin recovery credibility (margins below pre-Revlimid despite 50% India base). Bino Pathiparampil questioned $1B feasibility ($360M annual contribution from new products with binary approvals). Management held guidance but ceded points: tendency to deflect to "transit phase" without timeline.
Accounting change & India growth — Saion Mukharji, Nomura
PartialOverall reported 2%, adjusted ~4% YoY. Impact primarily South Africa. India 12% includes Yurpeak ₹80 Cr (~1.5%) and licensed products; balance from organic base at market-leading rates.
India organic growth — Saion Mukharji, Nomura
AnsweredIQVIA data at 15.4% on Rx; ₹80 Cr from Yurpeak is 1.5%. Analyst's independent calc lands on 7-8%; management did not rebut, implying base is mid-single digits.
South Africa tender decline — Saion Mukharji, Nomura
AnsweredTender business has declined; impact will continue through year. Private market growing 6.5% faster than market 5.7%, but currency hedges and accounting change mask it in headline.
US $1B guidance feasibility — Damayanti Kerai, HSBC
PartialYes, unchanged. New products are large; base not big enough for delta. Visibility comes from successful approvals and Ventolin scale-up in coming quarters.
EBITDA margin guidance vs Q1 delivery — Damayanti Kerai, HSBC
AnsweredBroadly unchanged. Guidance predicated on launches and margin improvement (sequential path).
Gross margin drivers and FY27 trajectory — Vivek Agrawal, Citi
PartialNot steady-state margin. Capex for launches committed (facilities, staffing) but products not yet approved; war costs (1-2%); product mix. Temporary transit phase; gradual improvement expected sequentially.
North America $1B: product-by-product breakdown — Bino Pathiparampil, Elara Capital
PartialAll very sizable opportunities. Assumes current competitive position unchanged. See large opportunity; don't expect competitive position to shift in 9 months.
Ventolin ramp timing — Vishal Manchanda, Systematix
AnsweredCommenced commercial shipments at current scale. Work ongoing; full ramp expected towards end of financial year (Q4).
Yurpeak traction and obesity market dynamics — Shyam Srinivasan, Goldman Sachs
AnsweredOur bet on tirzepatide (dual mode). High-involvement therapy; need prescriber guidance. Reached #2 after Mounjaro. Generic market crowded but different segment. Progressive growth expected as patient comfort builds.
Peptide launch constraints — Tushar Manudhane, Motilal Oswal
AnsweredHighly complex product; launch contingent on overcoming complexity, not litigation or patent variables. Can launch on FDA approval. Product off-patent. Awaiting approval; ready to launch upon clearance.
India field force & MR scaling — Tushar Manudhane, Motilal Oswal
Answered~12,000 field force. Not looking at significant manpower additions this year (added heavily last 2 years). Focus on productivity initiatives and reorganization within same headcount.
India acute portfolio trend — Tushar Manudhane, Motilal Oswal
AnsweredIn line with market on acute; strong beat on respiratory (key chronic); chronic momentum strong. Acute tracking market.
Margin recovery path and timeline — Vivek Agrawal, Citi (follow-up)
DodgedRefrain from next-year guidance. Direction clear: current level below steady-state. 18.5-20% for FY27 reaffirmed. Expect improvements in coming quarters (sequential trajectory).
Guidance
North America $1B revenue run rate by end FY27
MediumQ1 $162M; needs $938M in 9 months from 4 pending US FDA approvals (3 respiratory, 1 peptide). Ventolin ramp to Q4. Timing binary; competitive position assumed stable.
FY27 EBITDA margin 18.5-20%
MediumQ1 delivered 16.7% (180 bps below floor). Management maintains guidance is "broadly unchanged" but contingent on new product approvals coming through and sequential margin recovery. Capex drag expected to ease as facilities utilized.
CapEx increased vs prior year for organic growth, manufacturing readiness, R&D
HighR&D ₹486 Cr (6.8% of revenue) in Q1. Facilities staffed and batches ready for launches pending approvals; capex committed regardless of approval timing.
Risks the call surfaced
Regulatory execution risk (North America)
HighNorth America $1B guidance entirely contingent on FDA approvals for 3 respiratory assets and 1 peptide (unspecified). Q1 $162M vs implied $200-250M quarterly required. Any slip cascades to full-year miss.
Margin compression (profitability)
HighQ1 16.7% EBITDA vs 18.5-20% FY27 guidance (180 bps shortfall). Management attributes to launch capex (facilities ready, no revenue), war costs (1-2%), product mix. No timeline given for recovery to guidance range.
Earnings decline (profit pool)
HighPAT ₹786 Cr vs ₹1,288 Cr prior year Q1 (-39.2%). Revenue up only 2.3%. Gap suggests either structural cost inflation, margin compression, or one-off charges not fully disclosed. No management explanation in prepared remarks.
India organic growth slowdown
MediumReported 12% India growth but Yurpeak ₹80 Cr (~1.5% of total), licensed products, and accounting change adjustments removed imply ~7-8% organic base. Market-leading Rx (15.4%) is real, but analyst pushback suggests base momentum weaker than headline.
South Africa market headwinds
MediumReported -5% YoY (rupee terms). Private market growing 6.5% faster than market (5.7%) but overshadowed by tender decline (expected to persist) and 23% currency hedging impact. Structural shift away from tender business.
Competitive intensity (respiratory/peptide)
MediumVentolin has 6-month CGT exclusivity; Advair now has 3-4 competitors (down from premium opportunity). Peptide is said to be first-mover potential but complexity high. Market share assumptions may be optimistic if competition arrives faster than expected.
Lanreotide contingency
LowExplicitly excluded from FY27 projections. Two-pronged approach (Pharmathene remediation + US site tech transfer) running in parallel but timing "fluid" per management. No revenue expected in FY27.
Management
Score 6/10. Transparent on challenges (margin miss, war costs, launch delays) but evasive on underlying earnings decline. Q&A showed analysts pushing back credibly (Saion on real India growth, Vivek on margin recovery path, Bino on $1B feasibility). CFO transitioning; new appointee introduced. Track record mixed. Prior FY26 guidance (18.5-20% EBITDA) not yet met in Q1 (16.7%). Ventolin approved and launched on time (positive). Advair now 3-4 competitors vs prior hope for $100M+ (revised down). North America $1B still pending 4 approvals.
1 · Q2-Q3 FY27
Generic Ventolin ramp-up; 3 respiratory assets + 1 peptide FDA approvals and launches
2 · Q3-Q4 FY27
Winter season (seasonal strength for respiratory); higher-margin seasonal mix
3 · Within 9 months
North America reach $1B exit run rate (requires ~$938M from pending approvals)
Reaffirmed $1B and 18.5-20% guidance but execution risk high.
Record Revenue, Earnings Collapse — A ₹502 Crore Shortfall Unexplained
Cipla hit an all-time Q1 revenue record of ₹7,119 Cr, but profit fell 39% to ₹786 Cr. Management blames launch capex and war costs—but the numbers don't fully close the gap, and guidance reaffirmed despite a 180 bps margin miss.
The gap that defines the quarter
₹7,119 Cr
+2.3% (record Q1 absolute, modest organic)
₹786 Cr
-39.2% (₹502 Cr absolute drop vs prior year)
16.7%
-180 bps vs 18.5% guidance floor
On the headline, Cipla delivered its highest-ever Q1 revenue. But earnings went backward 39%—a ₹502 Cr absolute drop despite revenue up just 2.3%. The quarter's real story is in that gap. Management attributes the weakness to launch capex (facilities and manufacturing ready, awaiting FDA approvals), war costs (quantified at 1–2% of revenue, or ~₹71–143 Cr), and product mix. Those are real headwinds. But 1–2% war impact accounts for only ₹71–143 Cr of the ₹502 Cr PAT decline. The full earnings collapse remains unexplained.
Where the shortfall sits
The company frames Q1 as a "transit phase"—a temporary trough before margins recover toward the 18.5–20% FY27 guidance as new products launch and facilities ramp. That framing asks for faith. But the Q1 data shows margin compression (16.7% vs 18.5% floor), and management has not provided a quarter-by-quarter recovery roadmap. When pressed on next-year guidance in the Q&A, the CFO deflected: "Refrain from next-year guidance." The market heard defensiveness.
Highest ever Q1 revenue at ₹7,100 Cr
Delivered ₹7,119.3 Cr; claim verified
Supported
One India 12% YoY growth reflects strong base business momentum
Yurpeak ₹80 Cr = ~1.5% of growth; organic ex-new products ~7–8% per analyst calc
Overstated
EBITDA margin broadly unchanged vs 18.5–20% FY27 guidance
Q1 delivered 16.7% EBITDA, 180 bps below guidance floor
Contradicted
PAT ₹789 Cr this quarter
Delivered ₹785.5 Cr; negligible variance
Supported
$1B North America exit run rate achievable with 4 launches
Q1 $162M; needs 6.2x growth in 9 months from binary approvals
Mixed—dependent on regulatory wins
What changed on this call
Management held guidance but signaled a transition. EBITDA margins (18.5–20% FY27) are reaffirmed but now explicitly contingent on new product launches hitting their approval timelines—a higher execution bar than prior. Lanreotide, once a growth vector for FY27, is now pushed beyond the year with "timing fluid" pending regulatory remediation at Pharmathene and a US site transfer. India's organic momentum is weaker than the 12% headline suggests: stripping out Yurpeak (₹80 Cr, licensed from Eli Lilly) and adjusting for accounting changes, the base sits at ~7–8% YoY—mid-single digit, not double-digit. South Africa tender decline is expected to persist, masking an otherwise healthy private market (+6.5% growth vs. market +5.7%). Advair peak opportunity was revised down to ₹50–100 Cr from the prior assumption; competition is crowding the market faster than expected.
The bull-bear ledger
India market-leading Rx growth 15.4%, respiratory +15%
Chronic portfolio mix at 60.4%, target 65% within 2–3 years
Ventolin approved and launched Q1 with 6-month CGT exclusivity
Strong balance sheet: ₹9,494 Cr net cash post-₹1,050 Cr dividend
Sequential momentum (Q1 vs Q4): revenue +8.8%, PAT +44.8%
PAT collapsed 39% YoY despite 2.3% revenue growth
EBITDA margin 16.7% vs 18.5% guidance floor (180 bps miss)
North America $1B target depends entirely on 4 binary FDA approvals
India organic growth ~7–8% ex-new products (mid-single digit)
South Africa tender decline expected to persist
War costs 1–2% insufficient to explain 39% PAT drop
FII trimmed 137 bps to 22.49% after stock pop
Risks, ranked by how much they should concern a holder
Regulatory execution (North America FDA approvals)
HighFour pending approvals (3 respiratory, 1 peptide) are binary gates on $1B guidance. Q1 $162M run-rate needs 6.2x ramp in 9 months from regulatory approval alone. Any slip cascades to margin recovery and full-year miss.
Margin compression with no recovery path
HighQ1 16.7% vs 18.5% floor. Management has not provided quarter-by-quarter recovery roadmap. Capex drag and war costs expected to ease, but no timeline. Risk that 16.7% becomes the new floor if approvals slip or competitive intensity rises.
Earnings decline unexplained (39% PAT drop)
HighQuantified war costs (1–2%, ~₹71–143 Cr) and capex account for only part of ₹502 Cr PAT collapse. Inventory write-offs, product mix, and unquantified charges absorb the rest. Earnings quality weaker than revenue headline suggests.
India organic growth slowdown
MediumBase business excluding Yurpeak and licensed products is ~7–8% YoY (mid-single digit). While market-leading growth on chronic therapies is real, it masks that core momentum is decelerating. If base falls below 6%, India can't carry growth.
South Africa tender decline persistent
MediumTender business lost in prior year, impact flowing through 4 quarters. Private market growth (+6.5%) is real but doesn't offset headline (-5% reported). If tender headwind persists through FY27, South Africa becomes a drag.
Competitive intensity (Advair and peptide)
MediumAdvair peak revised down to $50–100M from $100M+ due to 3–4 competitors entering. Peptide is first-mover but manufacturing complexity is not permanent protection. Market share assumptions in $1B guidance may be optimistic if competition accelerates.
Lanreotide push-out beyond FY27
LowOnce a growth vector, now post-year pending regulatory remediation and site transfer. Conservative exclusion from guidance, but loss of upside if approvals slip further.
How the street is positioned
The stock popped on the result: +1.26% on day 1, then continued to +5.27% by day 5. The fact that the pop held—rather than fading—suggests the market did price in the margin miss and the PAT decline. But ownership data tells a different story. FII trimmed 137 basis points to 22.49% in Q4 FY26, signaling an exit into the strength of this quarter's price action. DII added 124 bps to 31.87%, suggesting domestic institutions are contrarian-buying the pullback. The stock is currently ₹1,473, trading above its 20-day, 50-day, and 200-day moving averages (₹1,437, ₹1,418, ₹1,406 respectively). But it's 11.94% below its all-time high, and RSI sits at 61.6 (neutral, not overbought). Volume is normal. The verdict: institutional divergence. Foreign money is unconvinced by the guidance reaffirmation; domestic money is betting on execution. The stock's resilience masks a credibility gap.
What to watch next (the three things that matter)
1 · Q2–Q3: Ventolin ramp and first FDA approvals
Ventolin launched in Q1 at "current scale"; management expects full ramp by Q4. The three respiratory assets and the peptide opportunity are under FDA review. Any approval in Q2–Q3 is a confidence signal for the $1B pathway. Any delay signals the 9-month timeline is slipping.
2 · Q2 EBITDA margin: does it trend back toward 18.5%?
If Q2 prints 17.2%+ (vs Q1 16.7%), sequential recovery is credible and the "transit phase" narrative holds. If Q2 stays at 16.7% or falls further, the margin floor has shifted lower, and the guidance becomes unreachable. This is the single most important number to track.
3 · India organic growth (ex-new products): is the base stabilizing?
Reported growth will remain in double digits as long as Yurpeak ramps. But the organic core—the chronic therapies that drive market-leading Rx growth—needs to stay above 6%. Any slip below 6% signals that India's high-single-digit days are behind, and the company is reliant entirely on new products to hit growth targets.
Cipla's Q1 was a classic tale of headline masking substance. Revenue hit a record ₹7,119 Cr, but earnings fell 39%. Guidance held, but Q1 execution missed by 180 bps on margin. The company is betting on four FDA approvals to hit a $1B North America run rate and on launch capex to ease as facilities ramp. That's a credible thesis if regulatory timelines hold. But Q1 showed that underlying earnings power has weakened—and management isn't ready to quantify the gap or provide a recovery roadmap.
This is not a momentum quarter, and not a disaster. It's a franchise asking its investors to believe in a pipeline-dependent model. FII are unconvinced (selling into the pop); DII are opportunistic (buying the dip). The stock sits above key moving averages but 12% below its all-time high.
The number to track from here is Q2 EBITDA margin. If it recovers toward 17.5%+, the "transit phase" narrative is real, and $1B North America is achievable. If it stays below 17%, the company is in a structural margin trough, not a cyclical one. That's the debate. The Q2 print will settle it.